Lyell Immunopharma (LYEL) Capital Expenditures (2020 - 2026)
Lyell Immunopharma recorded quarterly Capital Expenditures of $89000.0 in Q1 2026, down 70.72% quarter-over-quarter from $304000.0 in Q4 2025, and down 42.58% year-over-year from $155000.0 in Q1 2025.
Lyell Immunopharma's Capital Expenditures history runs 7 years deep, the most recent figure standing at $89000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 42.58% year-over-year to $89000.0; the TTM figure through Mar 2026 stood at $714000.0 (up 165.43% YoY), while the FY2025 annual figure was $780000.0, up 441.67% from the prior year.
- Capital Expenditures came in at $89000.0 for Q1 2026 at Lyell Immunopharma, down from $304000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $16.8 million in Q2 2022 to a low of -$18.4 million in Q4 2022.
- A 5-year average of $139235.3 and a median of $89000.0 in 2026 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures plunged 1122.22% in 2024 and soared 416.67% in 2025, its largest moves.
- Lyell Immunopharma's Capital Expenditures stood at -$18.4 million in 2022, then jumped by 100.15% to $27000.0 in 2023, then slumped by 1122.22% to -$276000.0 in 2024, then jumped by 210.14% to $304000.0 in 2025, then sank by 70.72% to $89000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $89000.0, $304000.0, and $62000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | 89,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89,000.00 |
| Mar 31, 2026 | 89,000.00 |
| Dec 31, 2025 | 304,000.00 |
| Dec 31, 2025 | 304,000.00 |
| Sep 30, 2025 | 62,000.00 |
| Sep 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 259,000.00 |
| Jun 30, 2025 | 259,000.00 |
| Mar 31, 2025 | 155,000.00 |
| Mar 31, 2025 | 155,000.00 |
| Dec 31, 2024 | -276,000.00 |
| Dec 31, 2024 | -276,000.00 |
| Sep 30, 2024 | 59,000.00 |
| Sep 30, 2024 | 59,000.00 |
| Jun 30, 2024 | 331,000.00 |
| Jun 30, 2024 | 331,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Sep 30, 2023 | -31,000.00 |
| Sep 30, 2023 | -31,000.00 |
| Jun 30, 2023 | -362,000.00 |
| Jun 30, 2023 | -362,000.00 |
| Mar 31, 2023 | 395,000.00 |
| Mar 31, 2023 | 395,000.00 |
| Dec 31, 2022 | -18.37 Mn |
| Dec 31, 2022 | -18.37 Mn |
| Sep 30, 2022 | 2.79 Mn |
| Sep 30, 2022 | 2.79 Mn |
| Jun 30, 2022 | 16.80 Mn |
| Jun 30, 2022 | 16.80 Mn |
| Mar 31, 2022 | 107,000.00 |
| Mar 31, 2022 | 107,000.00 |
| Dec 31, 2021 | 60.07 Mn |
| Dec 31, 2021 | 60.07 Mn |
| Sep 30, 2021 | -38.21 Mn |
| Sep 30, 2021 | -38.21 Mn |
| Jun 30, 2021 | 24.45 Mn |
| Jun 30, 2021 | 24.45 Mn |
| Mar 31, 2021 | 19.19 Mn |
| Mar 31, 2021 | 19.19 Mn |
| Dec 31, 2020 | -13.86 Mn |
| Dec 31, 2020 | -13.86 Mn |
| Sep 30, 2020 | 20.16 Mn |
| Sep 30, 2020 | 20.16 Mn |